Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial

AIMS: Over decades, left ventricular assist device (LVAD) technology has transitioned from less durable bulky pumps to smaller continuous‐flow pumps which have substantially improved long‐term outcomes and quality of life. Contemporary LVAD therapy is beleaguered by haemocompatibility‐related advers...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehra, Mandeep R., Crandall, Daniel L., Gustafsson, Finn, Jorde, Ulrich P., Katz, Jason N., Netuka, Ivan, Uriel, Nir, Connors, Jean M., Sood, Poornima, Heatley, Gerald, Pagani, Francis D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361946/
https://www.ncbi.nlm.nih.gov/pubmed/34142415
http://dx.doi.org/10.1002/ejhf.2275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361946/
https://www.ncbi.nlm.nih.gov/pubmed/34142415
http://dx.doi.org/10.1002/ejhf.2275

Ejemplares similares